Arrotex announces execs


Arrotex Pharmaceuticals has announced the executive team who will lead the integration, enablement and growth of the newly merged entity

As announced on 10 July 2019, Arrotex will be led by Dennis Bastas, who will take on the role of Chairman and CEO.

The company has now announced the executive team of Lisa Golden as Chief Commercial Officer, Andrew Burgess as Chief Financial Officer and Sue Morgan as Chief Legal Counsel who will lead the business with Mr Bastas.

Lisa Golden worked as Apotex Marketing Director, Asia Pacific for over four years, before taking the role of Director of Business Development and Strategy, Mundipharma Australia in October 2017.

Ms Golden completed her MBA with Australian Graduate School of Management (AGSM) in 2015 and is a Graduate of the Australian Institute Company Directors (GAICD).

Andrew Burgess is a Chartered Accountant and has served alongside Dennis Bastas for more than 10 years, most recently as the Chief Operating Officer, Arrow Pharmaceuticals.

Prior to this, Mr Burgess played a pivotal role in the success of both Central Healthcare Services and Ascent Pharmaceuticals in the role of Chief Operating Officer and Chief Financial Officer, respectively.

Dennis Bastas.

Sue Morgan has worked as General Manager, Arrow Pharmaceuticals for nearly four years. Prior to this, Ms Morgan worked as General Counsel and Company Secretary with Sigma Pharmaceuticals for over eight years.

Roger Millichamp, who led the Apotex Australia business for the past 12 years, has decided to use the opportunity of the merger to leave and pursue other opportunities after a short period of transition from Arrotex.

“The executive team selected, with more than 50 years combined generic pharmaceutical experience, boasts an extensive breadth and depth of knowledge and experience in the pharmaceutical space,” Mr Bastas said.

“The newly structured organisation reflects the size of the new entity and the responsibility and commitment we have to our pharmacy customers, our business partners and to Australian Patients.

“We all wish Roger Millichamp the best of luck with his future endeavours as he leaves behind a legacy of success built on strong leadership and hard work,” Mr Bastas said.

Previous Considerations when recommending an oral probiotic
Next Glaring risks in meds records, prescribing

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.